Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

A hydrogel platform delivering mesenchymal stem cell lysate for potential myocardial tissue repair.

Du Z., Zhang Q., Wang Q., Santerre P., Ma T., Ma P.

Animal Study on Cardiovascular Disease, Chronic Inflammation, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Front Bioeng Biotechnol (2026)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
42602045
DOI
10.3389/fbioe.2026.1855161

Abstract (original English)

Introduction Myocardial infarction is one of the most significant causes of death worldwide and the limited regenerative capacity of the myocardium often results in poor recovery after injury. Stem cell therapy has some promise for myocardial tissue repair, but clinical translation is hindered by poor cell survival and safety concerns, prompting the investigations of cell-free strategies such as stem cell-derived secretome or lysate. Methods In this study, a quaternized chitosan/tannic acid hydrogel was fabricated and characterized for its crosslinking stability, injectability and degradation kinetics. In addition, mouse adipose-derived mesenchymal stem cells (mADSCs) were isolated, characterized, and processed into cell-free lysate. The mADSCs lysate was then analyzed by TEM, NTA, Western blot and enzyme-linked immunosorbent assay. Results It was found that the mADSCs lysate contained abundant vesicles and a broad panel of cytokines/growth factors with anti-inflammatory, pro-angiogenic and antioxidant properties. Encapsulating the lysate within the hydrogel showed sustained release. The hydrogel-based delivery of mADSCs lysate could promote high metabolic activity and good cell number increases of H9c2-cardiomyocytes, L929-fibroblasts and human umbilical vein endothelial cells, demonstrating great potential for myocardial tissue repair applications. Discussion By integrating t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research